Yogenthiran Saunthararajah, MD, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, professor of Medicine, co-leader, Developmental Therapeutics Program of the Case Comprehensive Cancer Center, discusses mechanisms of resistance to 5-azacytidine and decitabine in patients with myelodysplastic syndromes-acute myeloid leukemia.
Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.
You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.
Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.
Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.
The beat on the people, devices, trends, and companies shaping healthcare... with Yue Xiong, PhD, Professor of Biochemistry and Biophysics, UNC Lineberger Comprehensive Cancer Center.
Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.
Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.
Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.
Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.
The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.
Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.
Although many labs study cancer as an all-or-nothing process, putting all metastable hybrid stages in the same bin, our laboratory at the University of Kentucky is exploring carcinogenesis as a continuum, from initiation through progression to maintenance. This approach has prompted us to focus on the role of epigenetics in cancer development.
Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.
The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer
Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).
Zachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.
More oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.
One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.
Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.
Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.
Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.
Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.
Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.